Have a personal or library account? Click to login
Almanac 2013: heart failure Cover

Almanac 2013: heart failure

Seminars in Cardiovascular Medicine
Volume 19 (2013): Issue 2 (December 2013)
By: Andrew L. Clark  
Open Access
|Jan 2014

References

  1. [1] National Heart Failure Audit April 2011-March 2012. National Centre for Cardiovascular Prevention and Outcomes, University College London, 2012. https://www.ucl.ac.uk/nicor/audits/heartfailure/additionalfiles/pdfs/annualreports/annual12.pdf
    Search in Google Scholar
  2. [2] Takeda A, Taylor SJ, Taylor RS, et al. Clinical service organisation for heart failure. Cochrane Database Syst Rev 2012;9:CD002752.10.1002/14651858.CD002752.pub3
    Search in Google Scholar
  3. [3] Holland R, Battersby J, Harvey I, et al. Systematic review of multidisciplinary interventions in heart failure. Heart 2005;91:899-906.10.1136/hrt.2004.048389
    Search in Google Scholar
  4. [4] Thomas R, Huntley A, Mann M, et al. Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials. Heart 2013;99:233-9.10.1136/heartjnl-2012-302313
    Search in Google Scholar
  5. [5] National Institute for Health and Care Excellence.Chronic heart failure. Clinical guideline 108. London, 2010.
    Search in Google Scholar
  6. [6] Al-Mohammad A, Mant J. The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. Heart 2011;97:411-16.10.1136/hrt.2010.214999
    Search in Google Scholar
  7. [7] National Institute for Health and Care Excellence.Chronic heart failure quality standard: QS9. London, 2011.
    Search in Google Scholar
  8. [8] Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013;6:606-19.10.1161/HHF.0b013e318291329a
    Search in Google Scholar
  9. [9] Mostofsky E, Rice MS, Levitan EB, et al. Habitual coffee consumption and risk of heart failure: a dose-response meta-analysis. Circ Heart Fail 2012;5:401-5.10.1161/CIRCHEARTFAILURE.112.967299
    Search in Google Scholar
  10. [10] McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
    Search in Google Scholar
  11. [11] Shah AS, Langrish JP, Nair H, et al. Global association of air pollution and heart failure: a systematic review and meta-analysis. Lancet. Published Online First: 9 July 2013. doi:10.1016/S0140-6736(08)61345-810.1016/S0140-6736(08)61345-8
    Search in Google Scholar
  12. [12] Aliti GB, Rabelo ER, Clausell N, et al. Aggressive fluid and sodium restriction in acute decompensated heart failure a randomized clinical trial. JAMA Intern Med 2013;173:1058-64.10.1001/jamainternmed.2013.552
    Search in Google Scholar
  13. [13] Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83.10.1016/j.jacc.2006.07.073
    Search in Google Scholar
  14. [14] Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre RELAX AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373:1429-39.10.1016/S0140-6736(09)60622-X
    Search in Google Scholar
  15. [15] Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39.10.1016/S0140-6736(12)61855-8
    Search in Google Scholar
  16. [16] http://www.novartis.com/newsroom/media-releases/en/2013/1711047.shtml (accessed 2 Jul 2013).
    Search in Google Scholar
  17. [17] Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-95.10.1016/S0140-6736(12)61227-6
    Search in Google Scholar
  18. [18] Cleland JG, Clark AL. Heart failure-does it matter whether LVEF is reduced? Lancet 2012;80:1363-5.10.1016/S0140-6736(12)61349-X
    Search in Google Scholar
  19. [19] Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013;1:103-11.10.1016/j.jchf.2012.12.004
    Search in Google Scholar
  20. [20] Goldacre B. Are clinical trial data shared sufficiently today? No. BMJ 2013;347:f1880.10.1136/bmj.f1880
    Search in Google Scholar
  21. [21] Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85.10.1016/S0140-6736(10)61198-1
    Search in Google Scholar
  22. [22] Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study.Clin Res Cardiol 2013;102:11-22.10.1007/s00392-012-0467-822575988
    Search in Google Scholar
  23. [23] National Institute for Health and Care Excellence.Ivabradine in chronic heart failure. 2012. http://www.nice.org.uk/TA267
    Search in Google Scholar
  24. [24] Hardman SM. Ivabradine in heart failure: NICE guidance.Heart. Published Online First: 18 June 2013. http://heart.bmj.com/content/early/2013/06/17/heartjnl-2012-303490.full.pdf+html?sid=29e1ec6a-5827-4d48-95ac-87be0a60b7c6
    Search in Google Scholar
  25. [25] Castagno D, Petrie MC, Claggett B, et al. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 2012;33:1137-41.10.1093/eurheartj/ehs00422408030
    Search in Google Scholar
  26. [26] Chemaly ER, Hajjar RJ, Lipskaia L. Molecular targets of current and prospective heart failure therapies. Heart 2013;99:992-1003.10.1136/heartjnl-2012-30297023349349
    Search in Google Scholar
  27. [27] McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.10.1161/CIRCHEARTFAILURE.107.74070419808266
    Search in Google Scholar
  28. [28] Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13.10.1056/NEJMoa120879923121378
    Search in Google Scholar
  29. [29] Gheorghiade M, Albaghdadi M, Zannad F, et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail 2011;13:100-6.10.1093/eurjhf/hfq20921123186
    Search in Google Scholar
  30. [30] Gheorghiade M, Böhm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013;309:1125-35.10.1001/jama.2013.195423478743
    Search in Google Scholar
  31. [31] Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011;13:107-14.10.1093/eurjhf/hfq21221169387
    Search in Google Scholar
  32. [32] McMurray JJ, Abraham WT, Dickstein K, et al. ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012;14:341-3.10.1093/eurjhf/hfs033330735722431404
    Search in Google Scholar
  33. [33] Phelan D, Thavendiranathan P, Collier P, et al. Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials. Heart 2012;98:1693-700.10.1136/heartjnl-2012-30217822791658
    Search in Google Scholar
  34. [34] Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.JAMA 2013;309:781-91.10.1001/jama.2013.90523443441
    Search in Google Scholar
  35. [35] Pandor A, Gomersall T, Stevens JW, et al. Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis. Heart. Published Online First: 16 May2013. http://heart.bmj.com/content/early/2013/05/15/heartjnl-2013-303811.full.pdf+html?sid=25776cbc-1e08-4e6f-abc1-638828de7d98
    Search in Google Scholar
  36. [36] Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med 2008;359:1009-17.10.1056/NEJMoa071098292251018768944
    Search in Google Scholar
  37. [37] Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming.N Engl J Med 2012;367:2275-83.10.1056/NEJMoa121110723131066
    Search in Google Scholar
  38. [38] Deyell MW, Qi A, Chakrabarti S, et al. Prognostic impact of inappropriate defibrillator shocks in a population cohort.Heart 2013;99:1250-5.10.1136/heartjnl-2012-30340723468515
    Search in Google Scholar
  39. [39] Hawkins NM, Petrie MC, Burgess MI, et al. Selecting patients for cardiac resynchronization therapy: the fallacy of echocardiographic dyssynchrony. J Am Coll Cardiol 2009;53:1944-59.10.1016/j.jacc.2008.11.06219460607
    Search in Google Scholar
  40. [40] Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure.N Engl J Med 2010;363:2385-95. 10.1056/NEJMoa100954021073365
    Search in Google Scholar
  41. [41] Witte KK. Cardiac resynchronisation therapy for chronic heart failure: predicting and measuring ‘response’. Heart 2013;99:293-4.10.1136/heartjnl-2012-30335923349344
    Search in Google Scholar
  42. [42] Mullens W, Verga T, Grimm RA, et al. Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol 2009;53:600-7.10.1016/j.jacc.2008.08.07919215835
    Search in Google Scholar
  43. [43] Verbrugge FH, Dupont M, Vercammen J, et al. Time from emerging heart failure symptoms to cardiac resynchronisation therapy: impact on clinical response. Heart 2013;99:314-19.10.1136/heartjnl-2012-30280723038789
    Search in Google Scholar
  44. [44] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation. Published Online First: 5 June2013. http://circ.ahajournals.org/content/early/2013/06/03/CIR.0b013e31829e8776.long
    Search in Google Scholar
  45. [45] Curtis AB, Worley SJ, Adamson PB, et al. Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators.Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013;368:1585-93.10.1056/NEJMoa121035623614585
    Search in Google Scholar
  46. [46] Schwartz PJ. Vagal stimulation for the treatment of heart failure: a translational success story. Heart 2012;98:1687-9.10.1136/heartjnl-2012-30229122962285
    Search in Google Scholar
  47. [47] Schwartz PJ, De Ferrari GM, Sanzo A, et al. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail 2008;10:884-91.10.1016/j.ejheart.2008.07.01618760668
    Search in Google Scholar
  48. [48] Hauptman PJ, Schwartz PJ, Gold MR, et al. Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J 2012;163:954-62.10.1016/j.ahj.2012.03.02122709747
    Search in Google Scholar
  49. [49] Banner NR, Bonser RS, Clark AL, et al. UK guidelines for referral and assessment of adults for heart transplantation.Heart 2011;97:1520-7.10.1136/heartjnl-2011-30004821856726
    Search in Google Scholar
  50. [50] Fröhlich GM, Holzmeister J, Hübler M, et al. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.Heart 2013;99:1158-65.10.1136/heartjnl-2013-304185
    Search in Google Scholar
  51. [51] Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012;379:895-904. 10.1016/S0140-6736(12)60195-0
    Search in Google Scholar
DOI: https://doi.org/10.2478/semcard-2013-0007 | Journal eISSN: 1822-7767
Journal RSS Feed
Language: English
Page range: 53 - 59
Published on: Jan 29, 2014
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Internal medicine, other,
Cardiology

© 2014 Andrew L. Clark, published by Sciendo
This work is licensed under the Creative Commons License.

Previous articleVolume 19 (2013): Issue 2 (December 2013)Next article